{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:39Z","timestamp":1791355779915,"version":"4.3.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify factors associated with early non-response to first-line treatment in children with primary immune thrombocytopenia (ITP), and to develop and externally validate a prediction model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective cohort study included 335 children with newly diagnosed primary ITP as the derivation cohort, including 255 responders and 80 non-responders. Clinical data obtained after admission were collected. Candidate variables were screened using correlation analysis and least absolute shrinkage and selection operator (LASSO) regression, followed by multivariable logistic regression to identify factors associated with early treatment non-response. Model discrimination was evaluated using the area under the receiver operating characteristic curve (AUC). An independent external validation cohort of 78 children was additionally included to assess model discrimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 335 children, 255 (76.1%) achieved a treatment response within 14 days after first-line therapy, whereas 80 (23.9%) did not. Multivariable analysis showed that older age (OR\u00a0=\u00a01.769, 95% CI: 1.629\u20131.920, P &amp;lt; 0.001), higher platelet-to-lymphocyte ratio (PLR) (OR\u00a0=\u00a01.622, 95% CI: 1.112\u20132.367, P\u00a0=\u00a00.012), and antinuclear antibody (ANA) positivity (OR\u00a0=\u00a03.142, 95% CI: 1.626\u20136.071, P &amp;lt; 0.001) were independently associated with early treatment non-response. The combined model incorporating age, PLR, and ANA achieved an AUC of 0.831 (95% CI: 0.778\u20130.885) in the derivation cohort and 0.718 (95% CI: 0.591\u20130.845) in the independent external validation cohort. Calibration was acceptable in both cohorts, with Hosmer\u2013Lemeshow P values of 0.609 and 0.220 and Brier scores of 0.129 and 0.137, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Older age, higher PLR, and ANA positivity were independently associated with early non-response to first-line treatment within 14 days in children with newly diagnosed primary ITP. These findings may help identify children at high risk of treatment non-response and support individualized monitoring and treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1983623","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:52:18Z","timestamp":1791352338000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors analysis and validation of early treatment non-response in children with primary ITP: a multicenter retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Mingwei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pediatric Center, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, Xinjiang Uyghur Autonomous Region, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Center, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, Xinjiang Uyghur Autonomous Region, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69635","article-title":"Diagnosis and management of immune thrombocytopenia in paediatrics: a comprehensive review","volume":"16","author":"Thakur","year":"2024","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012541","article-title":"The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia","volume":"8","author":"Neunert","year":"2024","journal-title":"Blood Adv"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4103\/singaporemedj.SMJ-2021-184","article-title":"Immune thrombocytopenia in infants: a retrospective study with comparison to toddlers","volume":"66","author":"Lee","year":"2025","journal-title":"Singapore Med J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13030341","article-title":"Predictors of remission in severe childhood immune thrombocytopenia","volume":"13","author":"Cheng","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2019.1635687","article-title":"The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States","volume":"31","author":"Shaw","year":"2020","journal-title":"Platelets"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2520097","article-title":"Epidemiology of immune thrombocytopenia in Yunnan Province and cytokine expression characteristics at different altitudes","volume":"30","author":"Yang","year":"2025","journal-title":"Hematology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071356","article-title":"Epidemiology and viral etiology of pediatric immune thrombocytopenia through Korean public health data analysis","volume":"10","author":"Lim","year":"2021","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.12701\/jyms.2022.00745","article-title":"Advances in management of pediatric chronic immune thrombocytopenia: a narrative review","volume":"40","author":"Lee","year":"2023","journal-title":"J Yeungnam Med Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/children11091051","article-title":"Experience with pediatric chronic immune thrombocytopenia over 30 years in the era before eltrombopag","volume":"11","author":"Koc","year":"2024","journal-title":"Children (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56120667","article-title":"Immune thrombocytopenia (ITP): current limitations in patient management","volume":"56","author":"Terrell","year":"2020","journal-title":"Med (Kaunas)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006480","article-title":"An update on pediatric ITP: differentiating primary ITP, IPD, and PID","volume":"140","author":"Grace","year":"2022","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29023","article-title":"Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia","volume":"68","author":"Shimano","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/children10060911","article-title":"Predictor factors for chronicity in immune thrombocytopenic purpura in children","volume":"10","author":"Rosu","year":"2023","journal-title":"Children (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2026.1864433","article-title":"Fifteen years of pediatric immune thrombocytopenia in a national cohort: chronicity, diagnostic challenges, and treatment patterns-single center experience","volume":"14","author":"Pregeljc","year":"2026","journal-title":"Front Pediatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18732","article-title":"The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia","volume":"202","author":"Liu","year":"2023","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/10760296251384282","article-title":"Evaluation of hemato-inflammatory parameters NLR, PLR and HPR in patients with immune thrombocytopenic purpura (ITP) in South-East Iran: a retrospective study","volume":"31","author":"Nakhaei Shamahmood","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70064","article-title":"Predictors of response to emergent therapies in paediatric immune thrombocytopenia","volume":"207","author":"O'Farrell","year":"2025","journal-title":"Br J Haematol"},{"key":"B19","article-title":"Diagnosis and treatment specifications for primary immune thrombocytopenia in children (2019 edition)","volume":"17","year":"2019","journal-title":"Chin J Gen Pract Clin Educ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140-20210509-00397","article-title":"Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021)","volume":"59","year":"2021","journal-title":"Chin J Pediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-570127","article-title":"Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis","volume":"124","author":"Heitink-Polle","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-007-0031-y","article-title":"Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura","volume":"24","author":"Altintas","year":"2007","journal-title":"J Thromb Thrombolysis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.64.1106","article-title":"Recent progress in immune thrombocytopenia pathophysiology and treatment","volume":"64","author":"Kato","year":"2023","journal-title":"Rinsho Ketsueki"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2026.01.011","article-title":"Immunopathology of immune thrombocytopenia","volume":"24","author":"Hillier","year":"2026","journal-title":"J Thromb Haemost"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301227","article-title":"Predicting the efficacy of glucocorticoids in pediatric primary immune thrombocytopenia using plasma proteomics","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/aob-20-57","article-title":"Immune thrombocytopenia: the patient\u2019s perspective","volume":"6","author":"Kruse","year":"2021","journal-title":"Ann Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27337","article-title":"Pediatric refractory chronic immune thrombocytopenia: identification, patients' characteristics, and outcome","volume":"99","author":"Pincez","year":"2024","journal-title":"Am J Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042163","article-title":"Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options","volume":"25","author":"Mititelu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1499014","article-title":"The function of T cells in immune thrombocytopenia","volume":"16","author":"Bu","year":"2025","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2304486","DOI":"10.1080\/16078454.2024.2304486","article-title":"Lymphocyte subpopulations: a potential predictor of a response in patients with immune thrombocytopenia","volume":"29","author":"Zibridova","year":"2024","journal-title":"Hematology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1679463","article-title":"Study on the influencing factors of the first-line treatment response to primary immune thrombocytopenia in children","volume":"13","author":"Zhang","year":"2025","journal-title":"Front Pediatr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s43054-025-00369-4","article-title":"The prognostic value of the systemic immune-inflammatory index and the systemic inflammation response index in pediatric immune thrombocytopenia","volume":"73","author":"Elmeazawy","year":"2025","journal-title":"Egyptian Pediatr Assoc Gazette"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20209","article-title":"Early response and long-term prognosis of paediatric ITP: exploration of future management strategies","volume":"207","author":"Zhang","year":"2025","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26736","article-title":"Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group Registry II participants","volume":"65","author":"Bennett","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/26348535231165594","article-title":"Frequency and clinical significance of antinuclear antibody positivity in immune thrombocytopenia in adults","volume":"17","author":"Munawar Ali","year":"2023","journal-title":"Plasmatology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103677","article-title":"Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP)","volume":"23","author":"Li","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000523","article-title":"ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases","volume":"8","author":"Liu","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06056-5","article-title":"Predictors for spontaneous remission in childhood chronic immune thrombocytopenia","volume":"103","author":"Yang","year":"2024","journal-title":"Ann Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1983623\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:52:21Z","timestamp":1791352341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1983623\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1983623"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1983623","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1983623"}}